A Study of IBI306 in Participants With Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

Also called NCT04709536

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 306 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04709536
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04709536. Randomized; triple masking; primary purpose treatment. Start 2021-02-09 (actual); primary completion 2021-11-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of IBI306 in Participants With Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
IBI306
Intervention (Drug)
Placebo
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04709536
Content hash
32a673d7b89c25b1ebcd6181dfeaf4e6f8ebaa4c7d90297eff43a04595bf14d5